MTB (Mycobacterium tuberculosis) KatG drug-resistant mutation site detection kit

The invention discloses an MTB (Mycobacterium tuberculosis) KatG drug-resistant mutation site detection kit. Through comparison with the MTB standard strain H37Rv sequence (NC_000962.3), an inventor finds two unreported mutation sites, namely, 294GGG and 296AT, from a clinically separated INH (isoniazid)-resistant MTB KatG gene. Meanwhile, the drug-resistant strain KatG gene only has the two mutation sites. Plasmid cloning and measurement of the MIC (minimum inhibitory concentration) value prove that mutations at 294GGG, 296ATC, 590AGG and 690GCC sites of the KatG gene can cause significant INH drug resistance. The mutations at the 590AGG and 690GCC sites occur spontaneously during plasmid cloning, and the mutations at the two sites are also not researched and reported through bioinformatics analysis. For the four mutation sites, the inventor researches and develops the MTB KatG drug-resistant mutation site detection kit, such as a PCR (polymerase chain reaction)-fluorescence probe method, and a molecular detection base is provided for early diagnosis of INH-resistant tuberculosis patients.